In IPASS (IRESSA Pan-Asia Study), clinically selected patients with pulmonary adenocarcinoma received first-line gefitinib or carboplatin/paclitaxel. This preplanned, exploratory analysis was conducted to increase understanding of the use of surrogate samples, such as serum, versus tumor biopsy samples for determining EGFR mutation status in the Japanese cohort (n ϭ 233).
T he epidermal growth factor receptor (EGFR) superfamily has been implicated in the regulation of tumor cell biology and, as such, has emerged as a therapeutic target. 1 In 2004, mutations in the EGFR were reported to be associated with sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs). [2] [3] [4] The presence of such mutations in tumor tissue is associated with a number of clinical factors including Asian origin, female sex, adenocarcinoma histology, and a neversmoking history, and these factors have additionally been correlated with response to gefitinib (IRESSA, AstraZeneca, Macclesfield, UK), an EGFR-TKI. 5 The IRESSA Pan-Asia Study (IPASS) compared gefitinib with carboplatin/paclitaxel as first-line treatment in 1217 never-smokers/light ex-smokers with advanced adenocarcinoma of the lung in East Asia. 6 Subgroup analysis of patients with EGFR mutations (n ϭ 261) detected in DNA derived from tumor tissue samples demonstrated significantly longer progression-free survival (PFS) with gefitinib versus carboplatin/paclitaxel (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.36 -0.64; p Ͻ 0.001). 6 In the EGFR mutation-negative (MϪ) subgroup (n ϭ 176), PFS was significantly longer with carboplatin/paclitaxel versus gefitinib (HR, 2.85; 95% CI, 2.05-3.98; p Ͻ 0.001). Objective response rates (ORR) were 71.2% versus 47.3% (p Ͻ 0.001) and 1.1% versus 23.5% (p ϭ 0.001) with gefitinib versus carboplatin/paclitaxel in EGFR Mϩ and MϪ patients, respectively.
The difficulties of collecting sufficient tumor tissue for biomarker analyses have stimulated interest in analyses using surrogate samples, such as serum and plasma samples, which frequently contain circulating free (cf) DNA derived from tumor tissues. Previous studies in relatively few patients had detected EGFR mutations in cfDNA in serum or plasma samples and suggested that using such methodology to predict response to gefitinib was worthy of further evaluation. [7] [8] [9] [10] [11] [12] However, most of these studies were retrospective.
Herein, we report the evaluation of EGFR mutations in cfDNA from serum samples of patients in the IPASS study recruited in Japan. This preplanned, exploratory analysis was conducted to increase the understanding of the use of surrogate samples, such as serum, versus tumor biopsy samples for determining EGFR mutation status.
MATERIALS AND METHODS

Study Design and Patients
Full details of the IPASS study design (ClinicalTrials. gov identifier NCT00322452) have been published previously. 6 Planned objectives of this substudy of IPASS were evaluations of efficacy between the gefitinib and carboplatin/ paclitaxel treatment groups by cfDNA EGFR mutation status from pretreatment serum samples and evaluation of the concordance between EGFR mutation status in pretreatment cfDNA versus tumor. Comparison of EGFR mutation status in pretreatment versus postprogression serum samples was also performed; however, not all patients with a pretreatment sample had a postprogression sample, which limited the comparison. In addition, comparisons with postprogression serum and pretreatment pleural effusion samples are reported in Supplemental Digital Content 1 (Methods http://links.lww.com/JTO/A152). Preplanned analysis of the Japanese subset of the IPASS population was performed to meet Japanese regulatory requirements.
All patients provided written informed consent. Provision of samples for biomarker research was optional and involved separate consent procedures for tumor and serum sampling. An independent ethics committee at each participating institution approved the study protocol. The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Guidelines for Good Clinical Practice, applicable regulatory requirements, and AstraZeneca's policy on bioethics.
Biomarker Analyses
Sample collection and DNA extraction are described in Supplemental Digital Content 1 (Methods http://links.lww. com/JTO/A152). EGFR mutations were detected using the DxS EGFR Mutation Test Kit for Research Use Only (DxS, Manchester, UK), which combines Amplification Refractory Mutation System (ARMS) (allele-specific polymerase chain reaction [PCR]) with the Scorpions real-time PCR technology. 13, 14 Modified run conditions and cutoffs (delta Ct values [dCt]) used to define Mϩ samples for cfDNA derived from serum and pleural effusion samples were as follows: 50 cycles of PCR were carried out and the dCt for exon 19 deletions was 12, L858R was 14, and T790M was 8 (for tumor DNA, 40 cycles of PCR were carried out and the dCt cutoffs were 9, 11, and 8, respectively). In analyses of tumor DNA, all 29 mutations detected by the kit were assayed (19 deletions in exon 19, L858R, T790M, L861Q, G719X [S, A, or C], S768I, and 3 insertions in exon 20); whereas for serum and pleural effusion samples, the 21 most common mutations (19 deletions in exon 19, L858R, and T790M) were assayed (to make the best use of limited cfDNA yield). Samples were tested in duplicate, and only if both replicates were positive for at least one of the mutations was the sample defined as Mϩ. Patients without a tumor sample evaluable for mutation analysis and samples which were not successfully analyzed were classified as EGFR mutation unknown. Biomarker samples were assayed blinded to clinical outcome and randomized treatment.
Statistical Analyses
Serum samples were collected for patients recruited in Japan and who consented to this optional analysis. Analyses of efficacy end points comparing treatment groups in the Japanese subset (intent-to-treat [ITT] population) were assessed as described previously for the overall IPASS population. 6 However, for the analyses in the cfDNA Mϩ and MϪ subgroups, the prespecified covariates of World Health Organization (WHO) performance status (PS), smoking history, and sex could not be included as covariates because of the small number of patients who had a WHO PS 2, were ex-smokers, or were males; therefore, models without covariates were used. Because of the lack of power to detect treatment differences, the result of the Japanese subset should be interpreted with caution, taking into account the associated variability and overlap in plausible range of effects (CIs). Analyses comparing treatment groups were performed for PFS (by Cox proportional hazards model) and ORR (by logistic regression model) in subgroups defined by cfDNA EGFR mutation status. A test for interaction between cfDNA EGFR mutation status (Mϩ or MϪ) and treatment was used to assess whether the PFS treatment effect was statistically different between subgroups.
Comparison of pretreatment cfDNA versus tumor EGFR mutations was based on the 21 mutations analyzed for cfDNA using patients with known mutation status (Mϩ or MϪ) in both samples. The sensitivity, specificity, positive and negative predictive values and their exact 95% CIs, and the kappa coefficient and 95% CI, for EGFR mutation status in serum samples, were evaluated assuming that the EGFR mutation status in tumor tissue was a true reflection of tumor biology. The proportion of concordance between cfDNA and tumor was calculated on a similar basis by excluding patients judged as unknown using either cfDNA or tumor samples.
RESULTS
Patients
In total, 233 patients from Japan were randomized to study treatment (19.1% of the overall IPASS population). Preplanned evaluations of efficacy, quality of life, and safety for the overall Japanese study population have been previously presented 15, 16 
EGFR Mutation Status
Demographic and Baseline Characteristics of Patients with Known EGFR Mutation Status
Key demographic and baseline characteristics for patients with known (i.e., evaluable) cfDNA or tumor EGFR mutation status were generally consistent with the overall Japanese study population (Table 1 ).
Pretreatment cfDNA EGFR Mutation Status and Clinical Outcomes
The subset of patients with known cfDNA EGFR mutation status could be assumed to be representative of the overall Japanese study population (and therefore the overall study population) as shown by similar PFS and ORR results ( Table 1) .
A significant interaction between cfDNA EGFR mutation status and treatment was evident for PFS (interaction test p ϭ 0.045). PFS was significantly longer with gefitinib than carboplatin/paclitaxel in the cfDNA EGFR Mϩ subgroup (HR, 0.29; 95% CI, 0.14 -0.60; p Ͻ 0.001) ( Figure 3A ). In the cfDNA EGFR MϪ subgroup, there were no significant differences for PFS with gefitinib compared with carboplatin/ paclitaxel (HR, 0.88; 95% CI, 0.61-1.28; p ϭ 0.50) ( Figure  3B ). However, the HR was not constant over time. We 4 ). Again, this subgroup included both tumor EGFR Mϩ and MϪ patients as described later.
The results for clinical outcome by EGFR mutation status (Mϩ, MϪ) for the Japanese subset of patients with known tumor EGFR mutation status (n ϭ 91) are included in Supplemental Digital Content 2 (Results http://links.lww.com/JTO/A153).
Comparison of EGFR Mutation Status in Pretreatment cfDNA and Tumor Tissue
A total of 108 patients had a known mutation result by cfDNA but not by tumor; 5 patients had a known mutation Of the 86 patients who had a known tumor and cfDNA mutation status, no false positives were identified (i.e., no samples were tumor MϪ but cfDNA Mϩ). All 22 patients identified as cfDNA EGFR Mϩ were tumor EGFR Mϩ, i.e., the positive predictive value was 100% (all samples that were cfDNA Mϩ were tumor Mϩ) and the specificity was 100% (all samples that were tumor MϪ were cfDNA MϪ) ( Table  2 ). However, the rate of false negatives was high: 29/51 (56.9%) of patients identified as tumor EGFR Mϩ were cfDNA EGFR MϪ ( Table 2 ).
EGFR Mutation Types in Pretreatment cfDNA and Tumor Tissue
Of the patients classified as EGFR Mϩ at pretreatment by both tumor and cfDNA, all had the same mutation type in Concordance ϭ 66.3% (cfDNA and tumor results agreed in 57 of 86 cases). b,c a Refers to the country of recruitment and not necessarily to racial origin. b Those with a known EGFR mutation status using both methods. c Kappa coefficient 0.38 (95% CI, 0.24 -0.53). cfDNA, circulating free DNA; CI, confidence interval; EGFR, epidermal growth factor receptor; ITT, intent-to-treat; Mϩ, mutation positive; MϪ, mutation negative.
tumor and cfDNA except one patient who had exon 20 T790M and exon 21 L858R by tumor but exon 20 T790M only by cfDNA (Table 3 ).
DISCUSSION
The feasibility of using cfDNA to detect EGFR mutations was assessed in the Japanese subset of patients from the IPASS study. The proportion of patients identified as EGFR Mϩ was lower when assessed in cfDNA (23.7%) compared with tumor tissue (61.5%). Although cfDNA results identified no false positives, a high rate of false negatives (56.9%) was observed, with more than half of the tumor Mϩ patients not detected by cfDNA testing (of patients with evaluable mutation status from both cfDNA and tumor). Further research into appropriate methods and analysis needs to be performed before it could be accepted as an option in the diagnostic or screening setting. If larger patient series confirmed the absence of false-positive results and demonstrated an improvement or lowering of false-negative results, serum testing may prove useful for patients for whom tumor samples are not available.
Testing of biopsied tumor tissue remains the current recommended method for EGFR mutation analysis. 8 However, tumor tissue is often difficult to obtain, particularly from patients with advanced non-small cell lung cancer (NSCLC), and a lack of tumor cells in a given sample and subsequently failure on pathological examination can make EGFR mutation analysis very difficult. The increased recognition of the relevance of mutation testing to treatment selection may stimulate efforts to better obtain tissue for EGFR mutation testing in the future. In the meantime, detection of EGFR mutation status in cfDNA derived from serum/plasma may allow patients without diagnostic tumor material the opportunity to benefit from personalized treatment and also has a use in the clinical trial setting where tumor material is not always available.
Although minimally invasive, the use of serum as a nontumor surrogate sample may be limited by the amount of cfDNA available in the sample, meaning that some positive samples are not detected. In addition, some patients may not have cf tumor DNA as their tumors may not be releasing this material into the bloodstream, giving rise to false-negative results. Because of the limited yields of cfDNA obtained from serum, two changes (in addition to duplicate tests) were made to the EGFR mutation ARMS kit used to detect EGFR mutations in this study: an increase in the number of PCR cycles and an alteration of the cutoffs used to define Mϩ samples (dCt values). Further analysis is underway to investigate whether these conditions are the most appropriate and whether less stringent settings could result in more true positives (fewer false negatives) while retaining no false positives.
There have been several reports on the detection of cfDNA EGFR mutation status using different methods. A significant correlation between cfDNA EGFR mutation status and clinical response to gefitinib was found in two previous small studies that assessed cfDNA EGFR mutation status using the ARMS method of detection, a highly sensitive (1% sensitive) targeted technique to detect specific known EGFR mutations. 9, 11 Other screening techniques detect all EGFR mutations, known and novel variants, by PCR amplification followed by sequencing, pyrosequencing, or melt analysis (10 -30% sensitivity). 8 However, although these methods are widely used for EGFR mutation analysis of DNA derived from tumor tissue, not all of these methods have demonstrated utility for EGFR mutation analysis of cfDNA. In a small study that used DNA sequencing to detect EGFR mutations in serum, mutations were more frequently observed in patients experiencing partial response or stable disease compared with those whose disease progressed, although the difference did not reach statistical significance. 10 No statistically significant association between cfDNA EGFR mutation status and PFS by multivariate analysis (HR, 1.48; 95% CI, 0.93-2.36; p ϭ 0.09) was found in the study by Rosell et al. 12 which assessed EGFR mutations by PCR-based methods in the presence of a protein nucleic acid (PNA) clamp in the cfDNA extracted from serum of 164 patients The categories are mutually exclusive. The categories "Exon 19 deletions and exon 20 T790M" and "Exon 19 deletions and exon 21 L858R" were 0 for both tumor and cfDNA and have been omitted from the table.
a Refers to the country of recruitment and not necessarily to racial origin. b Mutations that were tested in tumor tissue samples but not serum included: exon 20 insertion, exon 21 L861Q, exon 18 G719X, and exon 20 S768I. Two patients with tumor samples had these mutations (1 with exon 20 insertion and 1 with exon 21 L861Q). These patients were excluded from the comparative analysis of mutation detection by sample type.
cfDNA, circulating free DNA; EGFR, epidermal growth factor receptor; ITT, intent-to-treat. treated with erlotinib. In another study that used denaturing high-performance liquid chromatography to analyze for mutations in exons 19 and 21 from matched plasma and tumor samples, patients with plasma EGFR mutations had significantly higher ORR and prolonged PFS. 7 The present study using ARMS demonstrated that the treatment effect for the Japanese cfDNA EGFR Mϩ subgroup followed the same pattern as the tumor EGFR Mϩ subgroup of the overall IPASS population (i.e., PFS HR significantly in favor of gefitinib and higher ORR with gefitinib versus carboplatin/ paclitaxel). 6 There was a significant interaction between cfDNA EGFR mutation status and treatment for PFS. Any variance in concordance rates for mutation results between pretreatment serum versus tumor tissue (66.3% in our study and between 58 and 93% in previously reported studies) 7,9 -11 may be attributed to different methods of extraction, detection, run conditions, the size and yield of the DNA fragments, and the fact that cfDNA may not be present in the circulation of all patients with NSCLC. For example, targeted sequences amplified by ARMS are short, at 100 -150 bp, leading to decreased assay failure rates (particularly from formalin-fixed paraffin-embedded material or fragments of cfDNA) compared with sequencing methods, which tend to involve the amplification of longer target sequences of 150 -250 bp or above. 8, 13, 14, 17, 18 In patients who were cfDNA EGFR MϪ in this study, no significant difference for PFS was seen with gefitinib compared with carboplatin/paclitaxel; however, the HR was not constant over time (as was observed for the overall Japanese study population). These results should be interpreted with caution as there was a high rate of false negatives, and this subgroup is likely to include tumor EGFR Mϩ and MϪ patients.
In conclusion, these results merit further investigation to determine whether alternative samples, including serum or plasma, may be considered for determining EGFR mutation status in future, particularly in cases where diagnostic tumor material is not available. Currently, analysis of tumor material is the recommended method for determining EGFR mutation status.
